PolyPeptide Group Financials
| PPGN Stock | CHF 28.95 0.45 1.58% |
PolyPeptide |
Understanding current and past PolyPeptide Group Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of PolyPeptide Group's financial statements are interrelated, with each one affecting the others. For example, an increase in PolyPeptide Group's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in PolyPeptide Group's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of PolyPeptide Group AG. Check PolyPeptide Group's Beneish M Score to see the likelihood of PolyPeptide Group's management manipulating its earnings.
PolyPeptide Group Stock Summary
PolyPeptide Group competes with Bachem Holding, Siegfried Holding, VAT Group, Comet Holding, and Idorsia. PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. The company was founded in 1952 and is headquartered in Zug, Switzerland. POLYPEPTIDE is traded on Switzerland Exchange in Switzerland.| Instrument | Switzerland Stock View All |
| Exchange | SIX Swiss Exchange |
| ISIN | CH1110760852 |
| Business Address | Dammstrasse 19, Zug, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | www.polypeptide.com |
| Phone | 41 41 723 20 34 |
| Currency | CHF - Swiss Franc |
You should never invest in PolyPeptide Group without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of PolyPeptide Stock, because this is throwing your money away. Analyzing the key information contained in PolyPeptide Group's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
PolyPeptide Group Key Financial Ratios
There are many critical financial ratios that PolyPeptide Group's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that PolyPeptide Group reports annually and quarterly.| Return On Equity | 0.0809 | |||
| Return On Asset | 0.0467 | |||
| Target Price | 28.68 | |||
| Z Score | 33.0 | |||
| Last Dividend Paid | 0.29 |
PolyPeptide Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PolyPeptide Group's current stock value. Our valuation model uses many indicators to compare PolyPeptide Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PolyPeptide Group competition to find correlations between indicators driving PolyPeptide Group's intrinsic value. More Info.PolyPeptide Group AG is considered to be number one stock in return on equity category among its peers. It is regarded fourth in return on asset category among its peers reporting about 0.58 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for PolyPeptide Group AG is roughly 1.73 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PolyPeptide Group's earnings, one of the primary drivers of an investment's value.PolyPeptide Group Systematic Risk
PolyPeptide Group's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. PolyPeptide Group volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on PolyPeptide Group correlated with the market. If Beta is less than 0 PolyPeptide Group generally moves in the opposite direction as compared to the market. If PolyPeptide Group Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PolyPeptide Group is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PolyPeptide Group is generally in the same direction as the market. If Beta > 1 PolyPeptide Group moves generally in the same direction as, but more than the movement of the benchmark.
PolyPeptide Group December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of PolyPeptide Group help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PolyPeptide Group AG. We use our internally-developed statistical techniques to arrive at the intrinsic value of PolyPeptide Group AG based on widely used predictive technical indicators. In general, we focus on analyzing PolyPeptide Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PolyPeptide Group's daily price indicators and compare them against related drivers.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 14.58 | |||
| Value At Risk | (3.13) | |||
| Potential Upside | 4.56 |
Additional Tools for PolyPeptide Stock Analysis
When running PolyPeptide Group's price analysis, check to measure PolyPeptide Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PolyPeptide Group is operating at the current time. Most of PolyPeptide Group's value examination focuses on studying past and present price action to predict the probability of PolyPeptide Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PolyPeptide Group's price. Additionally, you may evaluate how the addition of PolyPeptide Group to your portfolios can decrease your overall portfolio volatility.